Posaconazole

Contraindicated

Posaconazole Sertraline Explained Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Posaconazole Buprenorphine Belbuca Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Posaconazole Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of fatal toxicity Details Posaconazole Simvastatin Flolipid Explained Increased simvastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Posaconazole Aripiprazole Injection Abilify Increased ARIPiprazole exposure and an increased risk of QT interval prolongation Details Posaconazole Atorvastatin Atorvaliq Increased atorvastatin exposure, an increased posaconazole exposure and an increased risk of myopathy and rhabdomyolysis Details Posaconazole Alfuzosin UroXatral Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Posaconazole Bedaquiline Sirturo Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Posaconazole Dasatinib Phyrago Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Posaconazole Dihydroergotamine Injection DHE-45® Injection Increased dihydroergotamine exposure and an increased risk of ergotism Details Posaconazole Dihydroergotamine Nasal Spray Migranal Increased dihydroergotamine exposure and an increased risk of ergotism Details Posaconazole Dofetilide Tikosyn Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Posaconazole Encorafenib Braftovi Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Posaconazole Entrectinib Rozlytrek Increased posaconazole exposure, an increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation and tors... Details Posaconazole Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Posaconazole Fluvastatin Lescol Increased fluvastatin plasma concentration and increased risk of myopathy or rhabdomyolysis Details Posaconazole Glasdegib Daurismo Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Posaconazole Ivabradine Corlanor Increased ivabradine exposure, an increased risk of ivabradine-related adverse effects and an increased risk of QT prolongation Details Posaconazole Lefamulin Xenleta Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Posaconazole Loperamide Diamode Increased posaconazole exposure, an increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation and tors... Details Posaconazole Lovastatin Altocor® Increased lovastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Posaconazole Lurasidone Latuda Increased lurasidone exposure and risk of increased adverse events Details Posaconazole Naloxegol Movantik Increased naloxegol exposure and an increased risk of naloxegol-related adverse effects Details Posaconazole Nimodipine Nimotop Increased serum nimodipine concentrations Details

Major

Posaconazole Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Posaconazole Omeprazole Gastrobim Explained Increased omeprazole exposure and reduced posaconazole exposure Details Posaconazole Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Posaconazole Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Posaconazole Abrocitinib Cibinqo Explained Increased posaconazole exposure Details Posaconazole Acalabrutinib Calquence Increased acalabrutinib exposure Details Posaconazole Ado-Trastuzumab Emtansine Injection KADCYLA Increased exposure of cytotoxic component DM1 (maytansine derivative) and risk of toxicity Details Posaconazole Amisulpride Injection Barhemsys An increased risk of QT interval prolongation Details Posaconazole Apixaban Eliquis Explained Increased exposure of apixaban Details Posaconazole Arsenic Trioxide Trisenox Increased risk of QT interval prolongation Details Posaconazole Arsenic Trioxide Injection Trisenox Increased risk of QT interval prolongation Details Posaconazole Asciminib Scemblix Increased asciminib exposure and an increased risk of asciminib-related adverse effects Details Posaconazole Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Posaconazole Atogepant Qulipta Increased atogepant exposure Details Posaconazole Avapritinib Ayvakit Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Posaconazole Azathioprine Azasan An increased risk of hepatotoxicity Details